Clinical TrialMay 19, 2026, 08:32 AM
Lantheus to Present Clinical Data at ASCO 2026 Meeting
AI Summary
Lantheus Holdings, Inc. announced that it will feature data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 29 to June 2, 2026, in Chicago, IL. The presentations include a poster session on a Phase 1/2 study of LNTH-2403, a LRRC15-targeted 177lutetium-labeled monoclonal antibody, for patients with relapsed/refractory osteosarcoma. Additionally, a publication-only session will highlight real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer.
Key Highlights
- Lantheus to present data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026.
- Data includes a Phase 1/2 study of LNTH-2403, a 177lutetium-labeled monoclonal antibody, for relapsed/refractory osteosarcoma.
- The LNTH-2403 study will evaluate safety, tolerability, pharmacokinetics, radiation dosimetry, and anti-neoplastic activity.
- A publication-only session will feature real-world use data of piflufolastat F 18 in early-stage prostate cancer.
- The ASCO Annual Meeting will take place in Chicago, IL.
Price Impact
More from LNTH